Skip to content
Biotechnology, Medical Health Aged Care

The Future of Skin Science: InMode and ExoCoBio introduce the most clinically validated exosome technology to New Zealand’s aesthetic market.

InMode Australia 2 mins read

This introduction brings one of the world’s most advanced exosome technologies to New Zealand, with two exclusive events set to take place in:

• Auckland – July 15, 2025 | The Boathouse, Park Hyatt Auckland, from 6:30pm

• Christchurch – July 17, 2025 | Chateau on the Park, DoubleTree by Hilton, from 6:30pm

 

These curated evenings will showcase the powerful synergy between ASCE+ Exosomes and InMode’s Morpheus8 technology, and feature:

• Live treatment demonstrations

• Keynote presentations from leading experts in regenerative science

• Clinical case studies and exclusive launch offers for attending practitioners

 

Key Speakers:

Dr Jean Paul Chung, Aesthetic Physician & Educator (Sydney), will present clinical insights and protocols using ASCE+ in skin rejuvenation.

Mr Byong Seung Cho, CEO & CTO of ExoCoBio, South Korea, will offer a rare insider’s perspective into the research and development behind ASCE+, and its role in reshaping global skin health.

 

Powered by ExoSCRT™, ExoCoBio’s proprietary purification technology, ASCE+ Exosomes are designed to optimise cell-to-cell communication, stimulate repair, and visibly revitalise the skin. Backed by science and trusted globally, ASCE+ is now set to raise the standard for non-invasive skin regeneration in the New Zealand market.

 

Adding to this innovation is the InMode Optimas Max, a powerful multi-platform workstation designed to deliver advanced skin treatments across various modalities -including radiofrequency, IPL, and laser technologies. With applicators such as Morpheus8 Burst, Lumecca Peak, and Forma, Optimas Max offers unparalleled versatility for skin resurfacing, tightening, and pigmentation correction - all in one streamlined device. It enables clinics to offer results-driven treatments with minimal downtime and maximum efficacy.

 

When paired with ASCE+ Exosomes, the Optimas Max system becomes a next-generation aesthetic powerhouse. The synergy between energy-based modalities and regenerative exosome therapy enhances treatment outcomes dramatically - accelerating recovery, improving skin texture, and promoting lasting rejuvenation. This combination delivers a compelling value proposition for clinics and practitioners committed to offering cutting-edge, science-backed solutions for their patients.

 

RSVP – https://event.inmodeau.com/asce_exosomes_nz


About us:

About InMode Australia

InMode is a market leader in energy-based medical technologies, providing cutting-edge, clinically validated solutions across Australia and New Zealand.

 

About ExoCoBio

ExoCoBio is a globally recognised innovator in exosome therapeutics and regenerative aesthetics, dedicated to delivering science-driven skincare solutions through advanced biologics.


Contact details:

Media Contact:
Patricia Amalm
Mobile: 0499 197 069
Email:
[email protected]
Website:
www.inmode.com.au

Follow Us on Instagram

Media

More from this category

  • Indigenous, Medical Health Aged Care
  • 15/12/2025
  • 06:00
Aboriginal Medical Services Alliance Northern Territory (AMSANT) and Menzies School of Health

Leading Northern Territory program triples liver cancer survival rates for Aboriginal Territorians

The Aboriginal Medical Services Alliance Northern Territory (AMSANT) and Menzies School of Health Research (Menzies) say a Territory-designed hepatitis B program (Hep B PAST)…

  • Contains:
  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.